Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 110Esophageal Neoplasms 88Neoplasms 68Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 25Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 18Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

tislelizumab 2Oxaliplatin 2tremelimumab 1olaparib 1durvalumab 1apatinib 1Tegafur 1Immunotherapy, Adoptive 1Dacarbazine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunotherapy × Oxaliplatin × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡